Fredun Pharma Converts Promoter Warrants, Issues 40,000 Shares

Fredun Pharmaceuticals Limited has issued 40,000 equity shares to promoter Mrs. Daulat Nariman Medhora following the conversion of her warrants. The company confirmed receipt of the ₹3.75 crore balance payment for this transaction, with each share priced at ₹1,250.

Key Transaction Details

Fredun Pharmaceuticals Limited has completed a step in its capital restructuring by allotting 40,000 equity shares.

These shares were issued to promoter Mrs. Daulat Nariman Medhora from her previously held warrants.

The company confirmed receiving the final payment of ₹3.75 crore for the conversion.

Each equity share was issued at a price of ₹1,250, as per the warrant terms.

Significance for Fredun Pharma

This allotment increases the company's total outstanding equity shares.

It shows the promoter's ongoing confidence in the company's future via equity conversion.

The conversion means warrants are exercised, converting potential equity into actual shares, boosting its equity base.

Past Funding Context

Fredun Pharmaceuticals has managed its capital structure via preferential issues.

On December 29, 2025, the board approved a preferential issue of equity shares and convertible warrants at ₹1,250 each.

This followed an October 17, 2025, fundraising event that raised ₹153.26 crore via equity and warrants, with a balance due within 18 months.

The current allotment represents the exercise of some of these warrants by a promoter, with the ₹3.75 crore received completing the payment for these shares.

Impact of Allotment

• Fredun Pharmaceuticals' total equity share capital has increased.
• Promoter Mrs. Daulat Nariman Medhora's stake will be updated.
• Issued warrants are now converted equity, reducing outstanding warrants.
• This transaction supports the company's ongoing funding and capital management.

Regulatory Note

Fredun Pharmaceuticals Limited received an Adjudication Order from SEBI dated June 30, 2025, for alleged violations including failure to prepare financial statements for FY 2017-18 as per Indian Accounting Standards and non-compliance with corporate governance norms. No monetary penalty was imposed.

Industry Peers

Fredun Pharmaceuticals operates in the highly competitive Indian pharmaceutical sector, which includes major players like:

• Sun Pharmaceutical Industries Ltd.
• Cipla Limited
• Dr. Reddy's Laboratories Ltd.
• Lupin Limited

These companies are significantly larger and have extensive product portfolios and market reach.

Transaction Figures

• Balance consideration received for warrants: ₹3.75 crore (Q1 FY27).
• Shares allotted via warrant conversion: 40,000 (Q1 FY27).
• Issue price per share: ₹1,250 (Q1 FY27).

Investor Watchlist

• Monitor future shareholding patterns for changes in promoter stake.
• Track any further exercise of outstanding warrants by other warrant holders.
• Observe the company's financial reports for the impact of increased equity on per-share metrics.
• Keep an eye on any new product launches or business development activities from Fredun Pharmaceuticals.
• Review any upcoming board meetings or corporate actions announced by the company.